Suppr超能文献

在肾功能正常或受损情况下奈替米星的药代动力学。

Pharmacokinetics of netilmicin in the presence of normal or impaired renal function.

作者信息

Humbert G, Leroy A, Fillastre J P, Oksenhendler G

出版信息

Antimicrob Agents Chemother. 1978 Jul;14(1):40-4. doi: 10.1128/AAC.14.1.40.

Abstract

A pharmacokinetic study of netilmicin was conducted in 12 healthy subjects and 24 subjects with chronic renal failure. After intramuscular administrations of 2 and 3 mg of netilmicin per kg in normal subjects, the mean peak serum concentrations were 5.46 and 8.83 mug/ml, respectively. After intravenous infusions of identical doses, the mean maximum serum levels, occurring at the end of the infusion, were 11.79 and 15.75 mug/ml, respectively. The pharmacokinetic data were very similar via the two routes of administration and for the two doses. The elimination half-life was 2.20 h, and 80 to 90% of the injected dose was recovered in urine during the first 24 h. After intramuscular administration of 2 mg/kg in subjects with chronic renal impairment, the elimination half-life increased to 29.48 h, and urinary elimination was inversely related to the degree of impairment. A study was conducted throughout hemodialysis sessions: serum concentrations decreased by 63.3%. The linear relationships between the elimination rate constant and creatinine clearance and the elimination half-life and serum creatinine allowed us to establish dosage schedules according to the degree of renal failure.

摘要

对12名健康受试者和24名慢性肾衰竭受试者进行了奈替米星的药代动力学研究。正常受试者每千克体重肌内注射2毫克和3毫克奈替米星后,血清平均峰值浓度分别为5.46微克/毫升和8.83微克/毫升。静脉输注相同剂量后,输注结束时的血清平均最高水平分别为11.79微克/毫升和15.75微克/毫升。两种给药途径和两种剂量的药代动力学数据非常相似。消除半衰期为2.20小时,在最初24小时内,80%至90%的注射剂量在尿液中回收。慢性肾功能损害受试者每千克体重肌内注射2毫克后,消除半衰期延长至29.48小时,尿液消除与损害程度呈负相关。在整个血液透析过程中进行了一项研究:血清浓度下降了63.3%。消除速率常数与肌酐清除率以及消除半衰期与血清肌酐之间的线性关系使我们能够根据肾衰竭程度制定给药方案。

相似文献

1
Pharmacokinetics of netilmicin in the presence of normal or impaired renal function.
Antimicrob Agents Chemother. 1978 Jul;14(1):40-4. doi: 10.1128/AAC.14.1.40.
2
Pharmacokinetics of azlocillin in subjects with normal and impaired renal function.
Antimicrob Agents Chemother. 1980 Mar;17(3):344-9. doi: 10.1128/AAC.17.3.344.
3
Pharmacokinetics of moxalactam in subjects with normal and impaired renal function.
Antimicrob Agents Chemother. 1981 Jun;19(6):965-71. doi: 10.1128/AAC.19.6.965.
4
Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis.
Clin Pharmacokinet. 1978 Sep-Oct;3(5):395-406. doi: 10.2165/00003088-197803050-00005.
5
Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis.
Antimicrob Agents Chemother. 1978 Sep;14(3):403-7. doi: 10.1128/AAC.14.3.403.
6
Pharmacokinetics of cefepime in subjects with renal insufficiency.
Clin Pharmacol Ther. 1990 Sep;48(3):268-76. doi: 10.1038/clpt.1990.149.
7
Predicted tissue accumulation of netilmicin in patients.
Antimicrob Agents Chemother. 1981 Dec;20(6):714-7. doi: 10.1128/AAC.20.6.714.
8
Kinetics of netilmicin and gentamicin.
Clin Pharmacol Ther. 1978 May;23(5):591-7. doi: 10.1002/cpt1978235591.
9
Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis.
Int J Clin Pharmacol Ther Toxicol. 1988 Feb;26(2):84-7.
10
Pharmacokinetic properties of netilmicin in newborn infants.
Antimicrob Agents Chemother. 1979 Feb;15(2):246-53. doi: 10.1128/AAC.15.2.246.

引用本文的文献

3
Population pharmacokinetics of netilmicin in short-term prophylactic treatment.
Br J Clin Pharmacol. 2003 Jun;55(6):552-9. doi: 10.1046/j.1365-2125.2003.01783.x.
4
Pharmacokinetics and metabolism of 14C-isepamicin in humans following intravenous administration.
Antimicrob Agents Chemother. 1995 Oct;39(10):2201-3. doi: 10.1128/AAC.39.10.2201.
6
Tentative interpretive criteria for the diffusion susceptibility test using 30-microgram netilmicin disks.
Antimicrob Agents Chemother. 1980 Sep;18(3):487-90. doi: 10.1128/AAC.18.3.487.
7
Pharmacokinetic assessment of netilmicin in newborns and older children.
Infection. 1982;10(3):153-8. doi: 10.1007/BF01640766.
8
Prospective comparative study of efficacy and toxicity of netilmicin and amikacin.
Antimicrob Agents Chemother. 1980 Feb;17(2):217-25. doi: 10.1128/AAC.17.2.217.
10
Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1989 Nov;38(5):703-56. doi: 10.2165/00003495-198938050-00003.

本文引用的文献

2
Gentamicin pharmacokinetics during hemodialysis.
Kidney Int. 1974 Jul;6(1):38-44. doi: 10.1038/ki.1974.75.
5
Comparative nephrotoxicities of netilmicin and gentamicin in rats.
Antimicrob Agents Chemother. 1976 Nov;10(5):845-9. doi: 10.1128/AAC.10.5.845.
6
Clinical pharmacology of netilmicin.
Antimicrob Agents Chemother. 1977 Dec;12(6):717-20. doi: 10.1128/AAC.12.6.717.
7
Pharmacokinetic study of netilmicin.
Antimicrob Agents Chemother. 1977 Jul;12(1):122-3. doi: 10.1128/AAC.12.1.122.
8
Netilmicin and gentamicin: comparative pharmacology in humans.
Antimicrob Agents Chemother. 1977 Apr;11(4):609-14. doi: 10.1128/AAC.11.4.609.
9
10
Bactericidal efficacy of Sch 20569 and amikacin against gentamicin-sensitive and -resistant organisms.
Antimicrob Agents Chemother. 1976 Apr;9(4):595-9. doi: 10.1128/AAC.9.4.595.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验